Back to search

Article

mRNA-COVID19 vaccination can be considered safe and tolerable for frail patients

2022-01-21

Abstract excerpt

<h4>Background</h4> Frail patients are considered at relevant risk of complications due to COVID-19 infection and, for this reason, are prioritized candidates for vaccination. As these patients were originally not included in the registration trials, fear related to vaccine side-effects and disease worsening was one of the reasons for vaccine hesitancy. Herein we report the safety profile of the prospective, multi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
02d0a26e-4f8a-5395-92b5-47211dfa6005
DOI
10.1101/2022.01.18.22269351
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
mRNA-COVID19 vaccination can be considered safe and tolerable for frail patientsDOI 10.1101/2022.01.18.22269351
Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from GreeceSemantic proximity
Clinical Features and Vaccine Efficacy Analysis of COVID-19 patients in a Chongqing Shelter hospital in 2022Semantic proximity
Clinical Features and Vaccine Efficacy Analysis of COVID-19 patients in a Chongqing Shelter hospital in 2022Semantic proximity
Modeling the Anticipated Public Health Benefits of the Next-Generation COVID-19 mRNA-1283 vaccine: An Interim U.S. Population-Level Impact AssessmentSemantic proximity
Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in FranceSemantic proximity
Reactogenicity of COVID-19 vaccine in hemodialysis patients: a single-center retrospective studySemantic proximity
A 6-week time period may not be sufficient to identify potential adverse events following COVID-19 vaccinationSemantic proximity
Nature Of, Immune Reaction to and Side Effects of COVID-19 Vaccines: Synthesis of Information Including Exclusions from Ten Phase II Trials for Planning Vaccination ProgrammesSemantic proximity
Review on different COVID-19 vaccines approved for Emergency Use Listing by WHO until 11 July 2022: characterization, pharmacological properties, mechanism of action and adverse events.Semantic proximity
COVID-19 vaccine hesitancy among individuals with cancer, autoimmune diseases, and other serious comorbid conditionsSemantic proximity
Effectiveness of the 2023–2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19–related Hospitalizations and Medical Encounters Among Adults in the United StatesSemantic proximity
Immunogenicity of COVID-19 mRNA Vaccines in Immunocompromised Patients: A Systematic Review and Meta-AnalysisSemantic proximity
Select a neighboring publication to make it the new centre.